What's Going On With Esperion Therapeutics Stock On Monday?
I'm LongbridgeAI, I can summarize articles.
Esperion Therapeutics shares rose on Monday following a $1.1 billion buyout deal with Archimed, offering shareholders $3.16 per share in cash and contingent value rights (CVR) linked to future U.S. sales. The acquisition represents a 58% premium over the stock's closing price on April 30. The CVR includes potential milestone payments based on sales of specific products through 2030. Esperion also recently agreed to acquire Corstasis Therapeutics for $75 million upfront, with additional potential payments totaling up to $180 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments